Tratamento do Câncer Avançado do Ovário. Resultados com o AVC (Adriamicina, VM-26 (Teniposide) e Ciclofosfamida)

• Autor(a) principal: Valle, José Carlos do
• Data de Publicação: 2023
• Outros Autores: Sampaio, Ernani Francisco de Sena, Gomes Filho, Firmino de Azevedo, Soriano, Ivan Bastos, Figueiredo, Eurídice Maria de Almeida, Ribeiro, Celso Werneck
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Brasileira de Cancerologia (Online)
• Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/3497
• topic: Carcinoma Epitelial do Ovário/terapia; Carcinoma Epitelial do Ovário/tratamento farmacológico; Doxorrubicina; Teniposídeo; Ciclofosfamida; Carcinoma, Ovarian Epithelial/therapy; Carcinoma, Ovarian Epithelial/drug therapy; Doxorubicin; Teniposide; Cyclophosphamide; Carcinoma Epitelial de Ovario/terapia; Carcinoma Epitelial de Ovario/tratamiento farmacológico; Doxorrubicina; Tenipósido; Ciclofosfamida

Twenty four patients with advanced carcinoma of the ovary, predominantly of the epitelial type (stage III and IV) were treated with a new association of chemoterapeutic agents — VM 26 (TENIPOSIDE), ADRIAMYCIN and CYCLOPHOSPHAMIDE - (AVC). Three courses of A VC were given as preoperative chemotherapy followed by radical hysterectomy with omentectomy and removal of all possible celomic methastasis. Six courses of AVC were administered as adjuvant chemotherapy followed by laparoscopy and second-look for eventual search of remainig residual disease. Seventy per cent of all patients showed objective response. Of those, 10% gave complete response, although 60% gave only partial response. Two patients with complete response confirmed at a second-look operation remainened asymptomatic for a 26 months follow-up period. The average maintenance of therapeutic response was 8.5 months with a survival of 13 months. All patients with controlled disease (25%) have survival for 7.6 months (average) where as those with rapidiy Progressive disease (10%) were dead at the end of 4.5 months (average). The AVe - Surgery — AVC protocol has proven useful in control and survival of advanced carcinoma of the ovary. The toxicity has been considered (to be within) folerable limits.